April 24,Roche Releases 2025 Q1 Financial Report, First Quarter Revenue15.44 billion Swiss francs, an increase of 6% year-on-year(Calculated at constant exchange rates CER, the same below), Pharmaceutical sector revenue reachedCHF 11.949 billion, an increase of 8% year-on-year.Source of screenshot: Corporate earnings report (same below)The main growth drivers of the pharmaceutical sector areThe main growth driver is Phesgo.（Subcutaneous injection of Trastuzumab、Vabysmo（Faricimab、Xolair(Omalizumab)and Hemlibra（Emicizumab, with total sales reachingCHF 3.6 billion, representing a year-on-year increase of 700 million Swiss francs.In terms of regions, sales in the U.S. market for the pharmaceutical sector grew by 6%, sales in Europe increased by 5%, sales in Japan rose by 3%, and sales in international regions grew by 18%, among which...China Market Shows Strong Performance with 14% Sales Growth, Mainly Driven by Xofluza(Mabaloxavir)And the demand for Phesgo。Revenue in the oncology sector grew by 2%. Specifically, the top revenue contributor remainsHER2 Product Portfolio（Phesgo 、Perjeta andKadcyla）AndAtezolizumab（Tecentriq）。
Among them, HER2 ADC Trastuzumab Emtansine（Kadcyla）Year-on-year growth of 5%; Pertuzumab（Perjeta）Reduce by 10%; Subcutaneous injection of Trulicity（Phesgo）Increased by 52%. Sales of PD-L1 monoclonal antibody Tecentriq reachedCHF 8.7 billion。
In terms of individual drugs, multiple products have shown outstanding performance.Ocrelizumab, a CD20 monoclonal antibody for multiple sclerosis, and emicizumab, a bispecific antibody for hemophilia,Ophthalmology Bispecific Antibody Vabysmo Still Shows Strong Growth, Sales in 2025 Q1 Have Already Exceeded1 billion Swiss francs。In 2025, the milestones of Roche's pharmaceutical division are shown in the figure below.From the pipeline perspective, Roche has also made adjustments and updates to its pipeline.Overall, Roche reported a good start to the year with sales growing 6% year-over-year at constant exchange rates and achieved many significant milestones.According to the latest data, used for treatmentAlzheimer's DiseaseAndHemophilia ATwo potential new therapies will enter Phase III clinical trials. Meanwhile, cooperation with Zealand Pharma is underway.Amylin, as a potential novel independent weight-loss therapy, and withFixed-dose combination of incretin CT-388。
Moreover, Roche noted in its financial report that it is expanding its already robust operations in the United States, currently employing over 25,000 people, with 15 research and development centers and 13 manufacturing sites, and will be making further investments.$50 billion, continuing to meet the needs of American patients through highly innovative drugs and diagnostic methods.
Cover Source:Corporate LogoDisclaimer:This article is for information sharing only,不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)